ABOUT_US

HISTORY

  • 2020
    • 12.15 Incorporate ($600 million in capital)
  • 2021
    • 01.29 Completed a $410 million equity capital increase
      07 13 billion investment in Ildong Pharmaceutical
      07 Incorporated as a subsidiary of Ildong Pharmaceutical
      07 ~ 09 Completed Series A funding ($22.4 billion total, including $13 billion from Ildong Pharmaceuticals)
  • 2023
    • 08 FXR US IND approved by Ildong Pharmaceutical, Phase 1 clinical trial underway
      11 CDK Inhibitor Patent Application
  • 2024
    • 02 CXCR7 modulator patent application
      03 SOS1 inhibitor patent application